^
Association details:
| Biomarker: | ETS rearrangment |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
Excerpt:
...we implanted VCaP (ERG positive) or PC3-LACZ (ETS negative) cells and studied the impact of Olaparib (100mg/kg/day, IP) on xenograft growth. Importantly, we observed a significant reduction of tumor growth in the ETS-rearranged cell line relative to that of the vehicle control, but no change was observed in the ETS-negative control cell line (p = 0.002) suggesting preferential sensitivity of ETS-positive tumors...
DOI:
10.1016%2Fj.ccr.2011.04.010